Pharvaris (NASDAQ:PHVS) CEO Berndt Modig Sells 2,292 Shares of Stock

Pharvaris N.V. (NASDAQ:PHVS) CEO Berndt Modig sold 2,292 shares of the business’s stock in a transaction that occurred on Thursday, April 16th. The shares were sold at an average price of $28.60, for a total value of $65,551.20. Following the completion of the sale, the chief executive officer directly owned 139,792 shares of the company’s stock, valued at approximately $3,998,051.20. The trade was a 1.61% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link.

Berndt Modig also recently made the following trade(s):

• On Thursday, April 9th, Berndt Modig sold 23,333 shares of Pharvaris stock. The stock was sold at an average price of $27.74, for a total transaction of $647,257.42.

Pharvaris Price Performance

NASDAQ PHVS opened at $28.97 on Tuesday. Pharvaris N.V. has a fifty-two week low of $13.81 and a fifty-two week high of $29.89. The stock’s 50-day moving average is $27.29 and its two-hundred day moving average is $25.72. The firm has a market cap of $1.89 billion, a P/E ratio of -8.60 and a beta of -2.58.

Pharvaris (NASDAQ:PHVS) last issued its quarterly earnings data on Friday, April 3rd. The company reported ($0.84) EPS for the quarter, missing analysts’ consensus estimates of ($0.69) by ($0.15). On average, equities analysts expect that Pharvaris N.V. will post -3.19 EPS for the current year.

Wall Street Analysts Forecast Growth

Several analysts recently issued reports on PHVS shares. Citigroup reaffirmed a “buy” rating on shares of Pharvaris in a report on Wednesday, April 15th. HC Wainwright reissued a “buy” rating and set a $60.00 price objective on shares of Pharvaris in a research report on Tuesday, March 3rd. Royal Bank Of Canada cut their price objective on Pharvaris from $52.00 to $51.00 and set an “outperform” rating for the company in a research report on Monday, April 6th. Wedbush boosted their price objective on Pharvaris from $41.00 to $42.00 and gave the stock an “outperform” rating in a research report on Tuesday, April 7th. Finally, Wall Street Zen cut Pharvaris from a “sell” rating to a “strong sell” rating in a research report on Monday, April 13th. Eleven investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $42.73.

Institutional Investors Weigh In On Pharvaris

A number of institutional investors have recently added to or reduced their stakes in the company. Seven Fleet Capital Management LP acquired a new stake in Pharvaris during the fourth quarter worth about $1,536,000. XTX Topco Ltd lifted its position in Pharvaris by 126.1% in the fourth quarter. XTX Topco Ltd now owns 18,568 shares of the company’s stock worth $515,000 after purchasing an additional 10,355 shares during the period. Ikarian Capital LLC lifted its position in Pharvaris by 131.7% in the fourth quarter. Ikarian Capital LLC now owns 486,856 shares of the company’s stock worth $13,510,000 after purchasing an additional 276,691 shares during the period. Virtus Investment Advisers LLC lifted its position in Pharvaris by 66.7% in the fourth quarter. Virtus Investment Advisers LLC now owns 11,011 shares of the company’s stock worth $306,000 after purchasing an additional 4,407 shares during the period. Finally, SummitTX Capital L.P. bought a new position in Pharvaris in the fourth quarter worth $634,000.

Pharvaris Company Profile

Pharvaris is a clinical-stage biopharmaceutical company focused on discovering and developing novel oral therapies for rare bradykinin-driven diseases. The company’s core mission is to address conditions characterized by uncontrolled activation of the plasma kallikrein-kinin system, with a primary emphasis on hereditary angioedema (HAE), a debilitating disorder marked by recurrent swelling episodes.

The company’s lead program, PHA121, is an investigational once-daily oral plasma kallikrein inhibitor designed for prophylactic treatment of HAE and is advancing through clinical trials.